Current Heart Failure Reports

, Volume 6, Issue 3, pp 182–190 | Cite as

Nitroprusside in decompensated heart failure: What should a clinician really know?

  • Cristina Opasich
  • Giovanni Cioffi
  • Alessandra Gualco
Article

Abstract

Sodium nitroprusside is an older intravenous vasodilator appropriate for acute hospital treatment of patients with congestive heart failure. It is a balanced arterial and venous vasodilator with a very short half-life, facilitating rapid titration. In general, it improves hemodynamic and clinical status by reducing systemic vascular resistance, left ventricular filling pressure, and increasing cardiac output. This review summarizes recently published literature and recent data regarding the use of this intravenous vasodilator in decompensated heart failure patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Miller RR, Vismara LA, DeMaria AN, et al.: Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume. Am J Cardiol 1976, 38:564–567.PubMedCrossRefGoogle Scholar
  2. 2.
    Mookherjee S, Keighley JF, Warner RA, et al.: Hemodynamic, ventilatory and blood gas changes during infusion of sodium nitroferricyanide (nitroprusside). Studies in patients with congestive heart failure. Chest 1977, 72:273–278.PubMedCrossRefGoogle Scholar
  3. 3.
    Franciosa JA, Silverstein SR: Hemodynamic effects of nitroprusside and furosemide in left ventricular failure. Clin Pharmacol Ther 1982, 32:62–69.PubMedGoogle Scholar
  4. 4.
    Yin FC, Guzman PA, Brin KP, et al.: Effect of nitroprusside on hydraulic vascular loads on the right and left ventricle of patients with heart failure. Circulation 1983, 67:1330–1339.PubMedGoogle Scholar
  5. 5.
    Stevenson LW, Tillisch JH: Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 1974, 6:1303–1308.Google Scholar
  6. 6.
    Stevenson LW, Bellil D, Grover-McKay M, et al.: Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987, 60:654–658.PubMedCrossRefGoogle Scholar
  7. 7.
    Stevenson LW, Tillisch JH, Hamilton M, et al.: Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990, 66:1348–1354.PubMedCrossRefGoogle Scholar
  8. 8.
    Hamilton MA, Stevenson LW, Child JS, et al.: Acute reduction of atrial overload during vasodilator and diuretic therapy in advanced congestive heart failure. Am J Cardiol 1990, 65:1209–1212.PubMedCrossRefGoogle Scholar
  9. 9.
    Masuyama T, Goar FG, Alderman EL, et al.: Effects of nitroprusside on transmitral flow velocity patterns in extreme heart failure: a combined hemodynamic and Doppler echocardiographic study of varying loading conditions. J Am Coll Cardiol 1990, 16:1175–1185.PubMedGoogle Scholar
  10. 10.
    Coddens J, Delooft T, Vandenbroucke G: Effects of dobutamine and/or nitroprusside on the pulmonary circulation in patients with pulmonary hypertension secondary to end-stage heart failure. J Cardiothorac Vasc Anesth 1993, 7:321–325.PubMedCrossRefGoogle Scholar
  11. 11.
    Capomolla S, Pozzoli M, Opasich C, et al.: Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. Am Heart J 1997, 134:1089–1098.PubMedCrossRefGoogle Scholar
  12. 12.
    Martins S, Soares RM, Do Rosario L, et al.: Early and medium term results of tailored therapy for heart failure. Rev Port Cardiol 2001, 20:261–282.PubMedGoogle Scholar
  13. 13.
    Capomolla S, Febo O, Opasich C, et al.: Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001, 3:601–610.PubMedCrossRefGoogle Scholar
  14. 14.
    Johnson W, Omland T, Hall C, et al.: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002, 39:1623–1629.PubMedCrossRefGoogle Scholar
  15. 15.
    Khot UN, Novaro GM, Popovic ZB, et al.: Treatment: vasodilatation with nitroprusside in symptomatic patients with severe aortic stenosis and congestive heart failure improves cardiac index. N Engl J Med 2003, 348:1756–1763.PubMedCrossRefGoogle Scholar
  16. 16.
    Cioffi G, Stefenelli C, Tarantini L, et al.: Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients > 70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. Am J Cardiol 2003, 92:1050–1056.PubMedCrossRefGoogle Scholar
  17. 17.
    Cioffi G, Tarantini L, Stefenelli C, et al.: Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. J Cardiac Fail 2006, 12:608–615.CrossRefGoogle Scholar
  18. 18.
    Olson TP, Frantz RP, Snyder EM, et al.: Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. Am Heart J 2007, 153:104. e1–104.e7.Google Scholar
  19. 19.
    Cioffi G, Tarantini L, Pulignano G, et al.: Prevalence, predictors and prognostic value of acute impairment in renal function during intensive unloading therapy in a community population hospitalized for decompensated heart failure. J Cardiovasc Med 2007, 8:419–427.Google Scholar
  20. 20.
    Mullens W, Abrahams Z, Francis GS, et al.: Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008, 52:200–207.PubMedCrossRefGoogle Scholar
  21. 21.
    Hollenberg SM: Vasodilators in acute heart failure. Heart Fail Rev 2007, 12:143–147.PubMedCrossRefGoogle Scholar
  22. 22.
    Elkayam U, Janmohamed M, Habib M, et al.: Vasodilators in the management of acute heart failure. Crit Care Med 2008, 36:S95–S105.PubMedCrossRefGoogle Scholar
  23. 23.
    Clyde WY: Vasodilator therapy for decompensated heart failure. J Am Coll Cardiol 2008, 52:208–210.CrossRefGoogle Scholar
  24. 24.
    Drugs.com: Nitroprusside (systemic). Accessible at http://www.drugs.com/ppa/nitroprusside-sodium.html. Accessed March 2009.
  25. 25.
    Moazemi K, Chana JS, Willard AM, et al.: Intravenous vasodilator therapy in congestive heart failure. Drugs Aging 2003, 20:485–508.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohn JN, Burke LP: Nitroprusside. Ann Intern Med 1979, 91:752–757.PubMedGoogle Scholar
  27. 27.
    Lavine SJ, Campbell CA, Held AC, et al.: Effect of inotropic and vasodilator therapy on left ventricular diastolic filling in dogs with severe left ventricular dysfunction. J Am Coll Cardiol 1990, 15:1165–1172.PubMedCrossRefGoogle Scholar
  28. 28.
    Leier CV, Bambach D, Thompson MJ, et al.: Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981, 48:1115–1123.PubMedCrossRefGoogle Scholar
  29. 29.
    Olivari MT, Levine TB, Cohn JN: Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 1983, 2:411–417.PubMedGoogle Scholar
  30. 30.
    Pozzoli M, Capomolla S, Pinna G, et al.: Doppler echocardiography reliably predicts pulmonary artery wedge pressure in patients with chronic heart failure with and without mitral regurgitation. J Am Coll Cardiol 1996, 27:883–893.PubMedCrossRefGoogle Scholar
  31. 31.
    Capomolla S, Febo O, Caporotondi A, et al.: Non-invasive estimation of right atrial pressure by combined Doppler echocardiographic measurements of the inferior vena cava in patients with congestive heart failure. Ital Heart J 2000, 1:684–690.PubMedGoogle Scholar
  32. 32.
    Gheorghiade M, Zannad F, Sopko G, et al.: Acute heart failure syndromes: current state and frame-work for future research. Circulation 2005, 112:3958–3968.PubMedCrossRefGoogle Scholar
  33. 33.
    Gheorghiade M, Abraham W, Albert N, et al.: Systolic blood pressure at admission, clinical characteristics and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296:2217–2226.PubMedCrossRefGoogle Scholar
  34. 34.
    Adams KF Jr, Fonarow GC, Emerman CL, et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209–216.PubMedCrossRefGoogle Scholar
  35. 35.
    Heart Failure Society of America: Executive summary: HFSA 2006 comprehensive heart failure practice guidelines. J Card Fail 2006, 12:10–38.Google Scholar
  36. 36.
    Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Stevenson LW: Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant 1991, 10:468–476.PubMedGoogle Scholar
  38. 38.
    Popovic ZB, Khot UN, Novaro GM, et al.: Effects of sodium nitroprusside in aortic stenosis associated with severe heart failure: pressure-volume loop analysis using a numerical model. Am J Physiol Heart Circ Physiol 2005, 288:H416–H423.PubMedCrossRefGoogle Scholar
  39. 39.
    Butler J, Forman DE, Abraham WT, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331–338.PubMedCrossRefGoogle Scholar
  40. 40.
    Stevenson LW, Massie BM, Francis GS: Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998, 135:S293–S309.PubMedCrossRefGoogle Scholar
  41. 41.
    Carrol JD, Lang RM, Neumann AL, et al.: The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy. Circulation 1986, 74:815–825.Google Scholar
  42. 42.
    Berkowitz C, Mckeever L, Croke RP, et al.: Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure. Circulation 1977, 56:918–924.PubMedGoogle Scholar
  43. 43.
    Costanzo MR, Johannes RS, Pine M, et al.: The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007, 154:267–277.PubMedCrossRefGoogle Scholar
  44. 44.
    Gallagher KL, Jones JK: Furosemide-induced ototoxicity. Ann Intern Med 1979, 91:744–745.PubMedGoogle Scholar
  45. 45.
    Silverberg D, Wexler D, Blum M, et al.: The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004, 13:163–170.PubMedCrossRefGoogle Scholar
  46. 46.
    Wienfeld MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999, 138:285–290.CrossRefGoogle Scholar
  47. 47.
    Bart BA, Goldsmith SR: Aggravated renal dysfunction and the acute management of advanced chronic heart disease. Am Heart J 1999, 138:200–202.PubMedCrossRefGoogle Scholar
  48. 48.
    Shlipak MG, Massie BM: The clinical challenge of cardiorenal syndrome. Circulation 2004, 110:1514–1517.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Cristina Opasich
    • 1
  • Giovanni Cioffi
  • Alessandra Gualco
  1. 1.Division of CardiologySalvatore Maugeri FoundationPaviaItaly

Personalised recommendations